

## NASCENT BIOTECH, INC.

### Progress on COVID-19, Cancer Development Should Drive NBIO to New Heights

Rob Goldman  
[rob@goldmanresearch.com](mailto:rob@goldmanresearch.com)

April 9, 2020

#### NASCENT BIOTECH, INC. (OTC – NBIO - \$0.25)

Industry: Biotechnology

Near-Term Price Target: \$0.50

#### COMPANY SNAPSHOT

Nascent Biotech, Inc. is a biotechnology company developing proprietary human Monoclonal Antibodies (mAbs) and immunotherapy for treatment of cancer. The Company's primary focus is the development of *Pritumumab*, a fully human monoclonal antibody for oncology indications and on cells infected by viruses such as coronaviruses. *Pritumumab* recognizes a unique antigen expressed on the surface of cancer cells and may be on cells infected by coronaviruses. Thus, *Pritumumab* is currently being developed to treat brain, pancreatic cancers and COVID-19.

#### KEY STATISTICS

Price as of 4/8/20	\$0.25
52 Week High – Low	\$0.35- \$0.052
Est. Shares Outstanding	44.7M
Market Capitalization	\$11.2M
Average Volume	78,691
Exchange	OTCQB

#### COMPANY INFORMATION

**Nascent Biotech, Inc.**  
 6330 Nancy Ridge Drive  
 San Diego CA 92121

Web: [www.NascentBiotech.com](http://www.NascentBiotech.com)  
 Email: [sean.carrick@nascentbiotech.com](mailto:sean.carrick@nascentbiotech.com)  
 Phone : 612.961.5656

#### INVESTMENT HIGHLIGHTS

**Conclusion:** We believe NBIO offers considerable 30-day upside for opportunistic investors, given upcoming milestones for NBIO's COVID-19 testing in progress and Cancer therapy development. Based on our analysis, NBIO's shares could reach the \$0.50 mark, if not higher, with greater gains throughout 2020, as additional milestones occur.

**Catalyst Background:** Due to the current health pandemic, investors are rabid for companies making legitimate, meaningful headway in the fight against COVID-19. The Company's lead therapeutic candidate, based on information published in the Journal of Biomedical Science, may have an impact in treatment of coronaviruses. *Pritumumab* may have the ability to interfere with the virus' binding to target cells, thus possibly eliminating deadly effects.

**Ahead of Competition?** Results of in vitro testing are forthcoming and if favorable, should direct future development activity, thus driving share interest, volume, and value. This is especially the case if preclinical work from cancer research is deemed applicable to viral infections.

**Valuation:** At current levels, we believe that NBIO's market value reflects its status as a preclinical cancer immunotherapy firm only, despite its present transition from preclinical to clinical status. Moreover, since NBIO is very much under the radar, the Street has assigned little to no value for its COVID-19 potential, which is considerable. Even @ \$0.50, the share price undervalues the potential for multiple, major indications that would serve COVID-19 and oncology patients' unmet needs. Separately, our near-term target could prove to be too low given the appetite for COVID-19 related stocks. Just yesterday Moleculin Biotech (NASDAQ – MBRX -\$1.27) more than doubled on over 160M traded shares.

## RECENT TRADING HISTORY FOR NBIO

(Source: [www.Stockta.com](http://www.Stockta.com))





## SENIOR ANALYST: ROBERT GOLDMAN

Rob Goldman founded Goldman Small Cap Research in 2009 and has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and *The Blue and White Fund*.

## ANALYST CERTIFICATION

I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.

## DISCLAIMER

This *Opportunity Research* report was prepared for informational purposes only.

*Goldman Small Cap Research*, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: *Goldman Select Research* and *Goldman Opportunity Research*. The *Select* format reflects the Firm's internally generated stock ideas along with economic and stock market outlooks. *Opportunity Research* reports, updates, trade alerts, and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored micro-cap research ideas that typically carry greater risks than those stocks covered in the *Select Research* category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats. Research reports on profiled stocks in the *Opportunity Research* format typically have a higher risk profile and may offer greater upside. *Goldman Small Cap Research* was not compensated for the production and distribution of this trade alert. All information contained in this report was provided by the Company via filings, press releases or its website, or through our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.

Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Such information and the opinions expressed are subject to change without notice.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. *Goldman Small Cap Research* did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. *Goldman Small Cap Research* relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A *Goldman Small Cap Research*

report or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. This report does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor's decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither *Goldman Small Cap Research*, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT IS PROVIDED "AS IS" WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, *TWO TRIANGLE CONSULTING GROUP, LLC* WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, *TWO TRIANGLE CONSULTING GROUP, LLC* WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: [www.goldmanresearch.com](http://www.goldmanresearch.com)